Cargando…
Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis
Background. Pancreatic enzyme replacement therapy is the standard of care for treatment of malabsorption in patients with cystic fibrosis (CF) and exocrine pancreatic insufficiency (PI). Aim. To evaluate efficacy and safety of a new formulation of pancrelipase (Ultrase MT20) in patients with CF and...
Autores principales: | Konstan, Michael W., Liou, Theodore G., Strausbaugh, Steven D., Ahrens, Richard, Kanga, Jamshed F., Graff, Gavin R., Moffett, Kathryn, Millard, Susan L., Nasr, Samya Z., Siméon, Édith, Spénard, Jean, Grondin, Josée |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004382/ https://www.ncbi.nlm.nih.gov/pubmed/21197074 http://dx.doi.org/10.1155/2010/898193 |
Ejemplares similares
-
Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis
por: Baker, Susan S
Publicado: (2008) -
Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis
por: Krishnamurty, Devi Mukkai, et al.
Publicado: (2009) -
Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency
por: Nakajima, Kei, et al.
Publicado: (2012) -
Effect of pancrelipase in preventing pancreatic dysfunction after
pancreaticoduodenectomy
por: Asano, Yukio, et al.
Publicado: (2019) -
Percutaneous closure of “hidden” left atrial appendage with Ultraseal device
por: Moreno-Samos, Jose Carlos, et al.
Publicado: (2019)